Downloads
Abstract
Objectives: Evaluating the overall survival results of the patients with received pegylated liposomal doxorubicin plus carboplatin regimen on recurrent epithelial ovarian cancer.
Methods: Retrospective and prospective study with 62 patients treated with pegyalated liposomal doxorubicin - carboplatin regimen for platinum - sensitive recurrent epithelial ovarian cancer at National Cancer Hospital from January 2015 to January 2022.
Results: Median overall survival (OS) was 40.2 month (CI 95%: 35.9 - 46.1), median duration of progression free survival was 10.2 weeks (95% CI: 5.4 - 15). Median overall survival, progression free survival were correlated with platinum sensitivity.
Conclusion: The combined pegylated liposomal doxorubicin - carboplatin is the appropriate regimen in term of efficacy on patients with platinum sensitive recurrent epithelial ovarian cancer.
References
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet ‐ Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65(2): 87-108.
PICCART, Martin J et al. Long - term follow - up confirms a survival advantage of the paclitaxel - cisplatin regimen over the cyclophosphamide - cisplatin combination in advanced ovarian cancer. International Journal of Gynecologic Cancer. 2003; 13( 2): 121-125.
Ozols RF, Rubin SC, Thomas G et al. WJ Hoskins CA Perez RC Young Epithelial ovarian cancer Principles and Practice of Gynecologic Oncology 919 - 922,2005 ed 4 Philadelphia, PA Lippincott Williams & Wilkins
Amate P, Huchon C, Dessapt AL et al. Ovarian cancer: sites of recurrence. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2013; 23(9): 1590-1596
Wagner U, Marth C, Largillier R et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum - sensitive ovarian cancer patients. Br J Cancer. 2012; 107(4): 588-591.
Harter P, Sehouli J, Vergote I et al. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021;385(23): 2123-2131.
The ICON and AGO collaborators. Paclitaxel plus platinum - based chemotherapy versus conventional platinum - based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO - OVAR - 2.2 trial. The Lancet. 2003; 361: 2099-2106.
Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum - sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Journal of Clinical Oncology. 2006; 24(29): 4699-4707.
Benedetti PP, De Vivo A, Bellati F. Secondary cytoreductive surgery in patients with platinum - sensitive recurrent ovarian cancer.Ann Surg Oncol. 2007;14(3):1136.
Champer M, Huang Y, Hou JY et al. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence. Gynecol Oncol. 2017;148(1): 19-27.
| Published | 10-08-2022 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 82 (2022) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.82.9 | |
| Keywords | Ung thư buồng trứng tái phát, nhạy platinum, CD Recurrent epithelial ovarian cancer, platinium-sensitive, CD |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital